Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | COPS5 | Q92905 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14659609 | 0.77 | DUT (0.32) | — | |
| SCHEMBL4903572 | 0.75 | PDE10A (0.47) | — | |
| SCHEMBL29289860 | 0.74 | MRGPRX4 (0.52) | — | |
| SCHEMBL4903480 | 0.73 | CCR1 (0.42) | COPS5MAPTHPGDMAP2K3 | |
| SCHEMBL22801137 | 0.72 | GABRP (0.36) | BACE1MAPTHPGDTACR1 | |
| SCHEMBL3534071 | 0.72 | NOS2 (0.38) | BACE1 | |
| SCHEMBL18109897 | 0.71 | GPBAR1 (0.49) | GPBAR1 | |
| SCHEMBL22689440 | 0.71 | ALOX15 (0.37) | BACE1MAPTHPGDTACR1GPBAR1 | |
| SCHEMBL1785770 | 0.71 | NUDT1 (0.46) | — | |
| SCHEMBL8545215 | 0.71 | MAPT (0.46) | MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858854-B1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-05-07 | — | — | EP | disclosed |
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | JAESCHKE GEORG | 2008-10-30 | — | — | US | disclosed |
| US-7414060-B2 | Pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1858854-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094639-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | HOFFMANN-LA ROCHE INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | CNR2, CNR1, CHRNA2 | BACE1 1369/4885COPS5 1446/4885MAPT 627/4885 |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | GRM3, GRM2, GRM1 | BACE1 220/4885COPS5 3314/4885MAPT 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.